261 related articles for article (PubMed ID: 36614156)
1. Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.
Zob DL; Augustin I; Caba L; Panzaru MC; Popa S; Popa AD; Florea L; Gorduza EV
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614156
[TBL] [Abstract][Full Text] [Related]
2. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
3. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Newell F; Hayward NK; Pritchard AL
Mol Cancer Res; 2021 Jun; 19(6):991-1004. PubMed ID: 33707307
[TBL] [Abstract][Full Text] [Related]
5. NF1 Mutations Are Common in Desmoplastic Melanoma.
Wiesner T; Kiuru M; Scott SN; Arcila M; Halpern AC; Hollmann T; Berger MF; Busam KJ
Am J Surg Pathol; 2015 Oct; 39(10):1357-62. PubMed ID: 26076063
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
7. Lack of distinct molecular profile of Primary Dermal Melanoma.
Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
[TBL] [Abstract][Full Text] [Related]
8. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract][Full Text] [Related]
9. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
Urso C
Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
[TBL] [Abstract][Full Text] [Related]
10. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
[TBL] [Abstract][Full Text] [Related]
11. Melanoma Genomics.
Newton-Bishop J; Bishop DT; Harland M
Acta Derm Venereol; 2020 Jun; 100(11):adv00138. PubMed ID: 32346746
[TBL] [Abstract][Full Text] [Related]
12. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
Yilmaz I; Gamsizkan M; Kucukodaci Z; Berber U; Demirel D; Haholu A; Narli G
Indian J Pathol Microbiol; 2015; 58(3):279-84. PubMed ID: 26275246
[TBL] [Abstract][Full Text] [Related]
13. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
14. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
15. Prognostic molecular biomarkers for cutaneous malignant melanoma.
Tanaka R; Koyanagi K; Narita N; Kuo C; Hoon DS
J Surg Oncol; 2011 Sep; 104(4):438-46. PubMed ID: 21557225
[TBL] [Abstract][Full Text] [Related]
16. Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis.
Yamamoto Y; Matsusaka K; Fukuyo M; Rahmutulla B; Matsue H; Kaneda A
Cancer Med; 2020 Oct; 9(19):7194-7204. PubMed ID: 32406600
[TBL] [Abstract][Full Text] [Related]
17.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
18. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
19. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
20. Molecular Genetics of Conjunctival Melanoma and Prognostic Value of
van Poppelen NM; van Ipenburg JA; van den Bosch Q; Vaarwater J; Brands T; Eussen B; Magielsen F; Dubbink HJ; Paridaens D; Brosens E; Naus N; de Klein A; Kiliç E; Verdijk RM
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]